These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30032392)

  • 1. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
    Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
    Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
    Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
    Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
    Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
    Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
    Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
    Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
    Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
    Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma].
    Fuji S
    Rinsho Ketsueki; 2018; 59(4):426-431. PubMed ID: 29743403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.
    Kamachi K; Shindo T; Miyahara M; Kitaura K; Akashi M; Shin-I T; Suzuki R; Oshima K; Kimura S
    Int J Hematol; 2019 Feb; 109(2):221-227. PubMed ID: 30368656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
    Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
    Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Tokunaga M; Yonekura K; Nakamura D; Haraguchi K; Tabuchi T; Fujino S; Hayashida M; Maekawa K; Arai A; Nakano N; Kamada Y; Kubota A; Inoue H; Owatari S; Takeuchi S; Takatsuka Y; Otsuka M; Hanada S; Matsumoto T; Yoshimitsu M; Ishitsuka K; Utsunomiya A
    Br J Haematol; 2018 May; 181(4):539-542. PubMed ID: 28369823
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab].
    Shodai A; Inoue H; Kamada Y; Fujino S; Tabuchi T; Arima N; Uchida Y; Hachiman M; Nakamura D; Yoshimitsu M; Ishitsuka K
    Rinsho Ketsueki; 2020; 61(6):612-616. PubMed ID: 32624533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mogamulizumab
    Phillips AA; Fields PA; Hermine O; Ramos JC; Beltran BE; Pereira J; Wandroo F; Feldman T; Taylor GP; Sawas A; Humphrey J; Kurman M; Moriya J; Dwyer K; Leoni M; Conlon K; Cook L; Gonsky J; Horwitz SM;
    Haematologica; 2019 May; 104(5):993-1003. PubMed ID: 30573506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
    Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.